Evidence map›Paper›PMID 39665558›Full record

ArticleAntimicrobial agents and chemotherapy2025

Stage-specific pharmacodynamic chloroquine and pyronaridine action on artemisinin ring-stage resistant Kelch C580Y mutation

Abeer Sayeed, Revie Atkinson, Peter G Vekilov, Jeffrey D Rimer, David J Sullivan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abeer SayeedDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Revie AtkinsonDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Peter G VekilovDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, USA.
Jeffrey D RimerDepartment of Chemical and Biomolecular Engineering, University of Houston, Houston, Texas, USA.
David J SullivanDepartment of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-0319-0578

Funding

Dual artemisinin action combats resistanceR01AI150763 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SULLIVAN, DAVID JOSEPH, VEKILOV, PETER G · 2021 to 2025
$2.9M
Bloomberg Family Foundation (The Bloomberg Family Foundation)JHSPH | Johns Hopkins Malaria Research Institute, Johns Hopkins Bloomberg School of Public HealthNIAID NIH HHS R01 AI150763
6 · The paper itself

Abstract

The antimalarial quinolines pyronaridine and chloroquine both inhibit hemozoin crystallization, predominately produced by

Indexed as

AntimalarialsArtemisininsChloroquineHemeproteinsNaphthyridinesPlasmodium falciparumDrug ResistanceHumansMalaria, FalciparumMutationAntimalarialsartemisininArtemisininsChloroquineHemeproteinshemozoinNaphthyridinespyronaridineartemisininchloroquinedrug resistancehemozoinpyronaridine

Identifiers

PMID39665558
PMCPMC11784244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.